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As I step down as editor-in-chief of Value in Health, I would like
to take a moment to reﬂect on my 8 years in this role. It has been
an enormously challenging but exciting period in my career. In
particular, there are two experiences that have been particularly
interesting and important to me. First, I have experienced ﬁrst-
hand the role that a professional journal plays in the evolution of
methods in a discipline. An example of this evolution that
occurred during my tenure as editor-in-chief is the introduction of
probabilistic sensitivity analysis (PSA) and the cost-effectiveness
acceptability curve (CEAC) as essential components of a cost-
effectiveness modeling analysis. Eight years ago, most cost-
effectiveness models submitted to Value in Health did not include
such analyses despite publications such as Doubilet et al. [1],
Critchﬁeld et al. [2], Fenwick et al. [3], Briggs & Fenn [4], and
Briggs et al. [5] recommending the use of these methods as an
integral part of decision analysis. Although submissions including
these analyses became much more common over the last 8 years,
many submissions during this period did not include such analyses
and this prompted intense discussions among the coeditors about
whether or not a PSA and CEAC should be required for all
cost-effectiveness models published in the journal. We ﬁnally
decided that this should not be a requirement. This was mostly
because of our reluctance to dictate methods to authors.
But we reckoned without the peer-review process. Our peer-
reviewers started asking for such analyses to be included in a
revised paper when they were not provided in the initial paper.
Generally, journal editors expect the authors to make changes in
their article to respond to all the peer-reviewer comments. So
now, the question changed from “Do we (the journal) require a
PSA and CEAC?” to “Do I (the coeditor) tell the authors that
they can ignore this reviewer comment if they can justify doing
so?” But a coeditor typically does not tell an author to ignore a
reviewer comment. So my advice now to anyone submitting
a cost-effectiveness analysis to the journal would be to include a
PSA and CEAC, not because the journal requires it, but because
our reviewers expect it!
The second important thing that I have experienced as editor-
in-chief is the value of the opinions of the coeditors and Editorial
Advisory Board in setting journal policy or processes. The
journal has greatly beneﬁted from following the opinions of
the majority of the coeditors or of the editorial advisory board.
The changes in journal policies or processes during my tenure
have been changes often suggested by coeditors or members of
the Editorial Advisory Board and always endorsed by the major-
ity of the coeditors and of the Editorial Advisory Board as well as
the ISPOR board and their Management Advisory Board. These
changes in journal policy or processes have sometimes been
changes that I did not initially agree with but, in hindsight, they
have always been ones that have kept the journal on a steady
course and with a growing reputation for high quality publica-
tions. These policy and process changes have included:
• a policy blinding reviewers to authors of an article;
• a policy requiring authors of sponsored articles to have
freedom to publish;
• a policy that supplements dedicated to a single product are
not acceptable supplement topics while other types of
single-sponsor supplements may be acceptable;
• a process that requires all supplement topics to be sent to
the coeditors and the Editorial Advisory Board for approval
before a contract is signed;
• a process for a formal and independent supplement review
process by special editors selected by the journal;
• a process for creating press releases for all accepted articles;
• a process for placing conference abstracts in separate
journal issues with “A” page numbers; and
• a process for articles going online early electronically before
the printed version.
I was privileged to follow Joel Hay, the ﬁrst editor-in-chief of
Value in Health. Joel had laid a very strong foundation for the
journal, setting up policies and procedures, getting the journal
publications listed on electronic databases includingMedline, and
working with his coeditors to demand high standards from
authors who wanted to publish in Value in Health. As well as this
strong foundation, I have also been fortunate to work with a team
of excellent coeditors and with an outstanding ISPOR editorial
staff, all of whom have been critical to the journal’s success. The
Editorial Advisory Board and the Management Advisory Board
and the publishers have also played important roles as journal
policies have evolved. And last, but certainly not least, I would like
to acknowledge the vital role that our submitting authors and our
reviewers have played in ensuring the quality of journal publica-
tions. With so many excellent people actively involved with the
journal during my tenure, I believe that the journal has continued
to grow in stature, serving both the research and decision-maker
communities. I know that the next era for the journal, under the
leadership of Mike Drummond and DanMullins, will be a period
of continued growth for the journal. I am delighted to be leaving
the journal in such capable hands.
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